This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Ginkgo (DNA) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
On Ginkgo's (DNA) third-quarter earnings call, investor focus is likely to be on the sales performance of its two business units ¿¿¿ Biosecurity and Cell Engineering.
Catalyst (CPRX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Catalyst's (CPRX) third-quarter 2023 earnings are expected to have been driven by the robust performances of its two marketed drugs, Firdapse and Fycompa CIII.
Bausch Health (BHC) Q3 Earnings & Sales Beat, '23 View Updated
by Zacks Equity Research
Bausch (BHC) surpasses third-quarter earnings and sales estimates as most of the business units post growth.
Intra-Cellular (ITCI) Q3 Earnings Top, Product Sales View Raised
by Zacks Equity Research
Intra-Cellular (ITCI) third-quarter 2023 earnings and revenues beat estimates. Caplyta sales continue to drive growth. The company raises its guidance for full-year 2023 Caplyta sales.
ImmunoGen (IMGN) Q3 Earnings Beat, Elahere Drives Revenues
by Zacks Equity Research
ImmunoGen's (IMGN) third-quarter 2023 earnings and revenues surpass estimates, driven by strong adoption of its sole-marketed drug Elahere. The company reiterates its revenue guidance.
Puma Biotech (PBYI) Q3 Earnings Beat, Revenues Lag Estimates
by Zacks Equity Research
Puma Biotech's (PBYI) third-quarter 2023 earnings beat estimates, while revenues miss the same. The company tightens the full-year revenue guidance.
Moderna (MRNA) Beats on Q3 Earnings & Sales, Expects Lower COVID Demand
by Zacks Equity Research
Moderna (MRNA) beats expectations for earnings and sales. However, the company projects lower-than-expected 2024 guidance, which likely led to a decline in share price after the earnings announcement.
Sarepta (SRPT) Q3 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Sarepta's (SRPT) Q3 earnings and sales beat estimates on the back of strong sales for recently approved DMD gene therapy Elevidys.
BioMarin (BMRN) Q3 Earnings in Line, Sales Miss, '23 View Cut
by Zacks Equity Research
BioMarin's (BMRN) Q3 earnings are in line with estimates but miss the mark on sales. The company lowered its 2023 guidance due to global pricing and reimbursement delays for Roctavian.
Zoetis' (ZTS) Q3 Earnings Beat, Revenues Miss by a Whisker
by Zacks Equity Research
Zoetis' (ZTS) third-quarter 2023 earnings surpass estimates. However, revenues fall marginally short. The strong performance of the companion animal portfolio drives year-over-year revenues.
Exelixis (EXEL) Q3 Earnings and Sales Miss, Annual View Updated
by Zacks Equity Research
Exelixis (EXEL) misses third-quarter 2023 earnings and sales estimates but tightens its annual revenue guidance and increases its R&D guidance.
Apellis (APLS) Q3 Loss Wider Than Expected, Syfovre Drives Sales
by Zacks Equity Research
Apellis' (APLS) third-quarter 2023 bottom line misses estimates, while the top line beats the same. Newly approved product, Syfovre, drives sales in the reported quarter.
Ligand Pharmaceuticals (LGND) Laps the Stock Market: Here's Why
by Zacks Equity Research
In the most recent trading session, Ligand Pharmaceuticals (LGND) closed at $53.30, indicating a +1.93% shift from the previous trading day.
GSK Beats on Q3 Earnings and Sales, Raises 2023 Guidance
by Zacks Equity Research
GSK's revenues benefit from strong growth across the Specialty Medicines and Vaccines segments. The company raises guidance for earnings and sales on the back of strong RSV vaccine sales.
Ligand Pharmaceuticals (LGND) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Ligand (LGND) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charles River (CRL) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Charles River's (CRL) CRADLE initiative and research models in North America and China are anticipated to have maintained their growth momentum in the third quarter.
Novo Nordisk (NVO) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Novo Nordisk (NVO) is likely to outperform third-quarter 2023 estimates, driven by increased Diabetes and Obesity Care product sales despite severe rivalry and pricing pressure in the United States.
Amgen (AMGN) Beats on Q3 Earnings Beat, Lags Sales, Ups View
by Zacks Equity Research
Amgen (AMGN) beats Q3 estimates for earnings but misses on sales. Following the acquisition of Horizon Therapeutics, it raises earnings and sales guidance for 2023.
Perrigo (PRGO) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the top line in the soon-to-be-reported quarter.
Viatris (VTRS) to Report Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
Viatris' (VTRS) Q3 results are likely to have been boosted by the momentum in its branded and generic businesses.
Gilead (GILD) Gears Up to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its third-quarter 2023 results.
Swedish Orphan Biovitrum (BIOVF) Q3 Earnings Miss Estimates
by Zacks Equity Research
Swedish Orphan Biovitrum (BIOVF) delivered earnings and revenue surprises of -44.44% and 7.69%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Regeneron (REGN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors' focus is likely to be on the performance of lead drug Eylea and the uptake of Eylea HD when Regeneron (REGN) reports its third-quarter 2023 results.
Ligand Pharmaceuticals (LGND) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
In the latest trading session, Ligand Pharmaceuticals (LGND) closed at $51.06, marking a +1.53% move from the previous day.